{"id":65727,"date":"2026-05-19T23:54:10","date_gmt":"2026-05-19T15:54:10","guid":{"rendered":"https:\/\/flcube.com\/?p=65727"},"modified":"2026-05-19T23:54:12","modified_gmt":"2026-05-19T15:54:12","slug":"bio-thera-solutions-secures-fda-approval-for-golimumab-biosimilars-immgolis-and-immgolis-intri","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65727","title":{"rendered":"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri"},"content":{"rendered":"\n<p><strong>Bio-Thera Solutions<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA: 688177<\/a>) announced it has received <strong>marketing approval from the U.S. Food and Drug Administration (FDA)<\/strong> for two <strong>golimumab biosimilars<\/strong>: <strong>Immgolis<\/strong> (subcutaneous) and <strong>Immgolis Intri<\/strong> (intravenous). The approvals position Bio-Thera as a <strong>global biosimilars leader<\/strong>, with the products already approved in the <strong>European Union<\/strong> and under review in <strong>Brazil and China<\/strong>, while commercial rights in the <strong>U.S., Canada, and India<\/strong> are held by partner <strong>Intas Pharmaceuticals Ltd.<\/strong> through a <strong>February 2025 licensing agreement<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approvals-amp-indications\">FDA Approvals &amp; Indications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Formulation<\/th><th>Approved Indications<\/th><\/tr><\/thead><tbody><tr><td><strong>Immgolis<\/strong><\/td><td>Subcutaneous injection<\/td><td>\u2022 Moderately to severely active rheumatoid arthritis (RA) + methotrexate<br>\u2022 Moderately to severely active ulcerative colitis (UC)<\/td><\/tr><tr><td><strong>Immgolis Intri<\/strong><\/td><td>Intravenous infusion<\/td><td>\u2022 Moderately to severely active rheumatoid arthritis (RA) + methotrexate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<p>Both biosimilars replicate <strong>Johnson &amp; Johnson&#8217;s Simponi\/Simponi Aria (golimumab)<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: <strong>Human IgG1 monoclonal antibody<\/strong> targeting <strong>tumor necrosis factor alpha (TNF-\u03b1)<\/strong><\/li>\n\n\n\n<li><strong>Anti-inflammatory Effects<\/strong>: Binding to TNF-\u03b1 reduces multiple inflammatory markers including <strong>C-reactive protein (CRP)<\/strong>, <strong>Interleukin-6 (IL-6)<\/strong>, <strong>ICAM-1<\/strong>, <strong>MMP-3<\/strong>, and <strong>VEGF<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: TNF-\u03b1 inhibition addresses core inflammatory pathways in autoimmune diseases<\/li>\n\n\n\n<li><strong>Biosimilarity<\/strong>: Demonstrated analytical, functional, and clinical similarity to reference products<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-regulatory-status-amp-market-access\">Global Regulatory Status &amp; Market Access<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Status<\/th><th>Commercial Rights<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>FDA approved (May 2026)<\/td><td>Intas Pharmaceuticals<\/td><\/tr><tr><td><strong>European Union<\/strong><\/td><td>Approved<\/td><td>Bio-Thera Solutions<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>Under marketing review<\/td><td>Bio-Thera Solutions<\/td><\/tr><tr><td><strong>Brazil<\/strong><\/td><td>Under marketing review<\/td><td>Bio-Thera Solutions<\/td><\/tr><tr><td><strong>Canada<\/strong><\/td><td>Rights granted<\/td><td>Intas Pharmaceuticals<\/td><\/tr><tr><td><strong>India<\/strong><\/td><td>Rights granted<\/td><td>Intas Pharmaceuticals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-framework\">Strategic Partnership Framework<\/h2>\n\n\n\n<p>The <strong>February 2025 licensing deal<\/strong> with <strong>Intas Pharmaceuticals Ltd.<\/strong> established a comprehensive commercial arrangement:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. Rights<\/strong>: Intas holds <strong>development, manufacturing, and commercial supply rights<\/strong> for the American market<\/li>\n\n\n\n<li><strong>Additional Territories<\/strong>: Intas also controls rights in <strong>Canada and India<\/strong> through prior agreements<\/li>\n\n\n\n<li><strong>Revenue Structure<\/strong>: Bio-Thera likely receives <strong>upfront payments, milestones, and royalties<\/strong> on Intas sales<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: Bio-Thera may supply drug product to Intas or license manufacturing technology<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TNF Inhibitor Market<\/strong>: Global anti-TNF market valued at <strong>$25+ billion annually<\/strong>, with biosimilars capturing increasing share<\/li>\n\n\n\n<li><strong>Golimumab Franchise<\/strong>: J&amp;J&#8217;s Simponi generated <strong>$2.1 billion in 2025 sales<\/strong>, representing substantial biosimilar opportunity<\/li>\n\n\n\n<li><strong>U.S. Biosimilar Adoption<\/strong>: Increasing acceptance of biosimilars in autoimmune diseases creates favorable launch environment<\/li>\n\n\n\n<li><strong>Pricing Dynamics<\/strong>: Expected <strong>30-40% discount<\/strong> to reference product supports payer adoption and market penetration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-bio-thera\">Strategic Implications for Bio-Thera<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Validation<\/strong>: FDA and EMA approvals validate Bio-Thera&#8217;s <strong>biosimilars development capabilities<\/strong><\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: Multiple geographic markets provide <strong>balanced revenue streams<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Momentum<\/strong>: Success supports advancement of Bio-Thera&#8217;s <strong>broad biosimilars pipeline<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing Scale<\/strong>: Commercial launches enable <strong>economies of scale<\/strong> in biologics manufacturing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-launch-strategy\">Commercial Launch Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. Market Entry<\/strong>: Intas will lead commercialization with established <strong>U.S. biosimilars infrastructure<\/strong><\/li>\n\n\n\n<li><strong>Payer Negotiations<\/strong>: Aggressive pricing strategy likely to secure <strong>favorable formulary placement<\/strong><\/li>\n\n\n\n<li><strong>Physician Education<\/strong>: Comprehensive medical affairs programs to support <strong>biosimilar adoption<\/strong><\/li>\n\n\n\n<li><strong>Supply Chain<\/strong>: Dual sourcing or technology transfer ensures <strong>supply reliability<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Formulation<\/strong>: Both subcutaneous and intravenous options provide <strong>comprehensive market coverage<\/strong><\/li>\n\n\n\n<li><strong>Multiple Indications<\/strong>: Broad label supports <strong>cross-specialty adoption<\/strong> in rheumatology and gastroenterology<\/li>\n\n\n\n<li><strong>Global Presence<\/strong>: Simultaneous availability in major markets creates <strong>brand recognition<\/strong><\/li>\n\n\n\n<li><strong>Quality Standards<\/strong>: Stringent regulatory approvals demonstrate <strong>manufacturing excellence<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-considerations\">Investment Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Recognition<\/strong>: Royalty stream from Intas provides <strong>predictable cash flow<\/strong> with limited commercial risk<\/li>\n\n\n\n<li><strong>Market Timing<\/strong>: Launch coincides with <strong>increasing biosimilar acceptance<\/strong> in complex autoimmune conditions<\/li>\n\n\n\n<li><strong>Pipeline Leverage<\/strong>: Manufacturing infrastructure supports <strong>additional biosimilar launches<\/strong><\/li>\n\n\n\n<li><strong>Valuation Impact<\/strong>: FDA approval likely to re-rate investor perception of Bio-Thera&#8217;s global capabilities<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial partnerships, and market opportunities. Actual results may differ due to risks including market adoption rates, competitive dynamics, pricing pressures, and partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Thera Solutions (SHA: 688177) announced it has received marketing approval from the U.S. Food and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,289,43,15,1055],"class_list":["post-65727","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-bio-thera-solutions","tag-biosimilars","tag-product-approvals","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio-Thera Solutions (SHA: 688177) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for two golimumab biosimilars: Immgolis (subcutaneous) and Immgolis Intri (intravenous). The approvals position Bio-Thera as a global biosimilars leader, with the products already approved in the European Union and under review in Brazil and China, while commercial rights in the U.S., Canada, and India are held by partner Intas Pharmaceuticals Ltd. through a February 2025 licensing agreement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65727\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri\" \/>\n<meta property=\"og:description\" content=\"Bio-Thera Solutions (SHA: 688177) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for two golimumab biosimilars: Immgolis (subcutaneous) and Immgolis Intri (intravenous). The approvals position Bio-Thera as a global biosimilars leader, with the products already approved in the European Union and under review in Brazil and China, while commercial rights in the U.S., Canada, and India are held by partner Intas Pharmaceuticals Ltd. through a February 2025 licensing agreement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65727\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T15:54:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T15:54:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65727#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65727\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri\",\"datePublished\":\"2026-05-19T15:54:10+00:00\",\"dateModified\":\"2026-05-19T15:54:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65727\"},\"wordCount\":594,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Bio-Thera Solutions\",\"Biosimilars\",\"Product approvals\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65727#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65727\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65727\",\"name\":\"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-19T15:54:10+00:00\",\"dateModified\":\"2026-05-19T15:54:12+00:00\",\"description\":\"Bio-Thera Solutions (SHA: 688177) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for two golimumab biosimilars: Immgolis (subcutaneous) and Immgolis Intri (intravenous). The approvals position Bio-Thera as a global biosimilars leader, with the products already approved in the European Union and under review in Brazil and China, while commercial rights in the U.S., Canada, and India are held by partner Intas Pharmaceuticals Ltd. through a February 2025 licensing agreement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65727#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65727\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65727#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri - Insight, China&#039;s Pharmaceutical Industry","description":"Bio-Thera Solutions (SHA: 688177) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for two golimumab biosimilars: Immgolis (subcutaneous) and Immgolis Intri (intravenous). The approvals position Bio-Thera as a global biosimilars leader, with the products already approved in the European Union and under review in Brazil and China, while commercial rights in the U.S., Canada, and India are held by partner Intas Pharmaceuticals Ltd. through a February 2025 licensing agreement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65727","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri","og_description":"Bio-Thera Solutions (SHA: 688177) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for two golimumab biosimilars: Immgolis (subcutaneous) and Immgolis Intri (intravenous). The approvals position Bio-Thera as a global biosimilars leader, with the products already approved in the European Union and under review in Brazil and China, while commercial rights in the U.S., Canada, and India are held by partner Intas Pharmaceuticals Ltd. through a February 2025 licensing agreement.","og_url":"https:\/\/flcube.com\/?p=65727","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T15:54:10+00:00","article_modified_time":"2026-05-19T15:54:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65727#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65727"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri","datePublished":"2026-05-19T15:54:10+00:00","dateModified":"2026-05-19T15:54:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65727"},"wordCount":594,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Bio-Thera Solutions","Biosimilars","Product approvals","SHA: 688177"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65727#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65727","url":"https:\/\/flcube.com\/?p=65727","name":"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-19T15:54:10+00:00","dateModified":"2026-05-19T15:54:12+00:00","description":"Bio-Thera Solutions (SHA: 688177) announced it has received marketing approval from the U.S. Food and Drug Administration (FDA) for two golimumab biosimilars: Immgolis (subcutaneous) and Immgolis Intri (intravenous). The approvals position Bio-Thera as a global biosimilars leader, with the products already approved in the European Union and under review in Brazil and China, while commercial rights in the U.S., Canada, and India are held by partner Intas Pharmaceuticals Ltd. through a February 2025 licensing agreement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65727#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65727"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65727#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65727"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65727\/revisions"}],"predecessor-version":[{"id":65728,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65727\/revisions\/65728"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}